Cidara to receive a $7 million milestone payment and is eligible to receive an additional $685 million in milestones, plus royalties (…) Responsibility for future development, manufacturing and commercialization activities of CD388 will be assumed by Janssen, which intends to transfer its rights and obligations under the agreement to another entity.

https://www.cidara.com/news/cidara-therapeutics-announces-janssens-election-to-proceed-under-its-license-agreement-relating-to-novel-drug-fc-conjugates-targeting-influenza/